WellSpan Health is expanding its Aidoc deployment across nine hospitals and 250+ care locations following proven radiology gains, while the AI platform adds advanced stroke imaging capabilities through partnerships with Cercare Medical and Circle CVI.
HotSpot Take:
WellSpan’s three-year journey from radiology pilot to enterprise-wide deployment demonstrates the maturation timeline health systems should expect when treating AI as infrastructure.
Clinical AI platform provider Aidoc is simultaneously scaling enterprise deployments and deepening clinical capabilities through two strategic moves announced in December 2025. WellSpan Health, the leading health system serving central Pennsylvania and northern Maryland, is expanding Aidoc’s aiOS (AI Operating System) across its entire nine-hospital, 250+ location network after demonstrating measurable clinical and operational gains in radiology since 2022. Concurrently, Aidoc announced partnerships with Cercare Medical and Circle CVI to integrate advanced MR Perfusion and automated ASPECTS scoring into its neurosciences portfolio, expanding capabilities for stroke and complex neurological care.
The dual announcements signal Aidoc’s positioning as both a proven enterprise infrastructure platform and an expanding clinical specialist, a combination increasingly critical as health systems move beyond pilot programs toward system-wide AI integration.
WellSpan’s Expansion: From Radiology Validation to Enterprise Scale
Since partnering with Aidoc in 2022, WellSpan Health has deployed the platform initially for radiology imaging triage and time-sensitive diagnosis acceleration. According to the company, Aidoc analyzed more than 200,000 patient cases across WellSpan in the past year, flagging over 10,000 potentially critical find,ings including pulmonary emboli, brain hemorrhages, and vessel occlusions.
The expansion brings 21 new AI-powered care pathways across seven service lines beyond radiology, including cardiology, vascular surgery, and neuroscience. With full aiOS implementation across WellSpan’s network serving more than one million patients annually, the health system positions itself among the early enterprise adopters treating AI as core clinical infrastructure rather than departmental point solutions.
“Aidoc has augmented our radiologists’ expertise for higher quality and safety, greater accuracy and a better work experience — especially important amid today’s physician shortage.” — Roxanna Gapstur, President and CEO of WellSpan Health
“At WellSpan, we’re building the future of health care, and our expanded partnership with Aidoc keeps us at the forefront of using AI to improve care,” said Roxanna Gapstur, President and CEO of WellSpan Health. “Aidoc has augmented our radiologists’ expertise for higher quality and safety, greater accuracy and a better work experience — especially important amid today’s physician shortage.”
WellSpan’s deployment demonstrates a strategic approach to AI adoption increasingly common among enterprise health systems: start with validated radiology use cases, measure outcomes rigorously, then scale systematically across specialties. The model addresses radiologist burnout and staffing shortages while potentially reducing diagnostic bottlenecks, operational imperatives that accelerate AI investment decisions regardless of pilot-program enthusiasm.
Strategic Architecture: aiOS as Operating System, Not Point Solution
The expansion incorporates Aidoc’s CARE foundation model platform, which received FDA Breakthrough Device Designation in September 2025 and represents a shift from narrow, single-disease algorithms to broad-spectrum diagnostic support. According to the company, CARE has generated three FDA-cleared solutions with additional derived capabilities in development.
aiOS integrates natively with WellSpan’s Epic EMR and imaging environment, enabling cross-specialty workflows without requiring radiologists or specialists to launch separate applications for different clinical conditions. The platform automatically routes patients with flagged findings to appropriate care teams, bridging identification with potential treatment coordination.
“WellSpan has mastered the motion of change management and clinical AI adoption. They’ve taken a bold, system-wide approach that treats AI as core clinical infrastructure, not a point solution.” — Elad Walach, co-founder and CEO of Aidoc
“WellSpan has mastered the motion of change management and clinical AI adoption,” said Elad Walach, co-founder and CEO of Aidoc. “They’ve taken a bold, system-wide approach that treats AI as core clinical infrastructure, not a point solution.”
The system-wide approach mirrors Sutter Health’s June 2025 partnership with Aidoc, which deployed aiOS across 24 hospitals and 200+ care sites serving 3.5 million Californians. These enterprise implementations suggest clinical AI platforms are consolidating around unified operating systems capable of supporting multiple specialties rather than proliferating as disconnected departmental tools.
Neurosciences Expansion: Advanced Stroke Imaging Through Strategic Partnerships
Parallel to enterprise scaling, Aidoc announced December 16 partnerships with Cercare Medical and Circle CVI to expand neurosciences capabilities with FDA-cleared and CE-marked algorithms for MR Perfusion analysis and automated ASPECTS (Alberta Stroke Program Early CT Score) assessment.
MR Perfusion provides physiological information about brain blood flow essential for identifying salvageable tissue in extended-window stroke patients and characterizing brain tumors. Cercare Medical’s metabolic perfusion solutions deliver high-quality perfusion maps based on proprietary biomarkers, enabling more precise tissue characterization in time-critical stroke decisions.
“Partnering with Aidoc allows us to bring our advanced MR Perfusion technology to a broader clinical audience through a unified, intelligent platform.” — Henrik Andersen, Chief Commercial Officer at Cercare Medical
“Partnering with Aidoc allows us to bring our advanced MR Perfusion technology to a broader clinical audience through a unified, intelligent platform,” said Henrik Andersen, Chief Commercial Officer at Cercare Medical. “This collaboration combines powerful imaging biomarkers with scalable AI integration, enhancing neurodiagnostic workflows and supporting faster, more informed treatment decisions for complex patient cases.”
Circle CVI’s automated ASPECTS scoring provides consistent, objective quantification of early ischemic changes on CT scans (a critical tool for rapidly assessing stroke severity and thrombectomy candidacy). The Canadian company’s StrokeSENS platform enhances reader performance with demonstrated improvements in sensitivity, specificity, and inter-reader agreement, reducing subjectivity in time-sensitive stroke evaluations.
“By embedding our automated ASPECTS into Aidoc’s comprehensive platform, we can help more stroke teams achieve faster, more reliable assessments, ultimately impacting patient pathways positively,” said Erkan Akyuz, CEO of Circle CVI.
The partnerships expand Aidoc’s existing neurosciences suite, which includes solutions for intracranial hemorrhage, vessel occlusions, CT perfusion, c-spine fractures, vertebral compression fractures, and brain aneurysms. Integrating MR Perfusion and ASPECTS capabilities enables consistent, data-driven decisions from initial imaging through intervention across neurology, neuroradiology, neurointervention, and neurosurgery disciplines.
Competitive Context: Platform Consolidation in Clinical AI
Aidoc’s dual-strategy approach, combining enterprise infrastructure with specialized clinical depth, positions the company amid intensifying competition in clinical AI platforms. RapidAI, Brainomix, and Viz.ai represent primary competitors in stroke and neurovascular imaging, each pursuing distinct market approaches.
RapidAI emphasizes “deep clinical AI” with extensive validation in landmark stroke trials (DEFUSE 2, SWIFT PRIME, EXTEND-IA, DEFUSE 3) and recently announced five new FDA clearances expanding beyond stroke into general radiology applications. Brainomix focuses on stroke imaging decision support with expansion into lung disease analysis. Viz.ai pioneered AI-driven stroke workflow coordination and received the first CMS New Technology Add-on Payment for AI software.
According to published comparative studies, algorithm performance varies significantly across platforms, with real-world accuracy depending heavily on case mix, imaging protocols, and integration quality. A 2025 European Radiology study noted that vendor-reported performance metrics often differ from clinical implementation results, emphasizing the importance of workflow integration and change management over algorithm specifications alone.
Aidoc’s strategy of building a unified operating system rather than standalone detection tools aligns with emerging health system preferences for consolidated platforms over proliferating point solutions. With 18 FDA clearances, deployment across 150+ U.S. health systems and 1,600 hospitals globally, and more than 100 million patient cases analyzed according to the company, Aidoc represents one of the largest real-world clinical AI footprints in medical imaging.
Implementation Realities: Change Management Over Algorithm Performance
WellSpan’s emphasis on “mastering the motion of change management” reflects a critical insight increasingly recognized in clinical AI deployment: successful implementation depends as much on workflow integration, clinician training, and organizational commitment as on algorithm accuracy.
Radiologist and specialist adoption requires demonstrable value: reducing cognitive load, accelerating workflows, and improving diagnostic confidence, without creating alert fatigue or workflow disruption. Health systems deploying AI must balance sensitivity (catching critical findings) with specificity (avoiding false positives that erode trust), manage integration across PACS, EMR, and communication platforms, and sustain organizational commitment through inevitable implementation challenges.
WellSpan’s three-year journey from initial radiology deployment to enterprise-wide expansion suggests a maturation timeline health systems should expect when treating AI as infrastructure rather than technology acquisition. The partnership model, where health systems co-develop capabilities and conduct peer-reviewed outcomes research, potentially accelerates both algorithm refinement and organizational learning.
Market Trajectory: From Pilot Programs to Core Infrastructure
The convergence of enterprise expansion (WellSpan, Sutter Health) and clinical specialization (neurosciences partnerships) reflects clinical AI’s evolution from experimental technology to operational necessity. Radiology staffing shortages, increasing imaging volumes, and intensifying pressure for faster diagnoses create structural demand for AI platforms regardless of innovation enthusiasm.
Foundation models like Aidoc’s CARE platform (capable of detecting multiple conditions simultaneously rather than requiring separate algorithms for each pathology) address a critical limitation of early clinical AI: algorithm proliferation. Radiologists facing dozens of point-solution algorithms, each with distinct interfaces and launch procedures, experience the opposite of workflow improvement. Unified platforms processing complete studies holistically represent a more sustainable scaling approach.
For WellSpan’s million-plus patients, the practical implications include potentially faster identification of time-sensitive conditions, more consistent diagnostic standards across the health system’s geographic footprint, and reduced bottlenecks in urgent imaging workflows. Stroke patients, in particular, stand to benefit from the enhanced neurosciences capabilities, where minutes can determine the difference between full recovery and permanent disability. For clinicians, successful implementation means augmented diagnostic confidence and reduced burnout rather than technology burden.
The expanded neurosciences capabilities through Cercare Medical and Circle CVI partnerships demonstrate platform evolution, not just accumulating more detection algorithms, but integrating specialized clinical insights that support complex decision-making across entire care pathways. As health systems navigate the transition from pilot programs to permanent infrastructure, the ultimate measure of success remains consistent: whether AI platforms help deliver faster, more accurate diagnoses that improve patient outcomes while supporting the clinicians who care for them.
– This original article was created with AI support.
